Evidence map›Paper›PMID 31570042›Full record

ArticlemAbs

Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis.

Claire Harris, Weichen Xu, Luigi Grassi, Chunlei Wang, Abigail Markle, Colin Hardman, Richard Stevens, Guillermo Miro-Quesada, Diane Hatton, Jihong Wang

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claire HarrisBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Cambridge , UK.ORCID 0000-0002-8695-7537
Weichen XuBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg , MD , USA.ORCID 0000-0002-2198-1122
Luigi GrassiBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Cambridge , UK.ORCID 0000-0002-6308-7540
Chunlei WangBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg , MD , USA.ORCID 0000-0001-9141-3297
Abigail MarkleBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg , MD , USA.
Colin HardmanData Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca , Cambridge , UK.ORCID 0000-0003-4992-1268
Richard StevensAntibody Discovery and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca , Cambridge , UK.
Guillermo Miro-QuesadaData & Quantitative Sciences, Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg , MD , USA.
Diane HattonBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Cambridge , UK.
Jihong WangBiopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca , Gaithersburg , MD , USA.ORCID 0000-0001-9271-0218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein primary structure is a potential critical quality attribute for biotherapeutics. Identifying and characterizing any sequence variants present is essential for product development. A sequence variant ~11 kDa larger than the expected IgG mass was observed by size-exclusion chromatography and two-dimensional liquid chromatography coupled with online mass spectrometry. Further characterization indicated that the 11 kDa was added to the heavy chain (HC) Fc domain. Despite the relatively large mass addition, only one unknown peptide was detected by peptide mapping. To decipher the sequence, the transcriptome of the manufacturing cell line was characterized by Illumina RNA-seq. Transcriptome reconstruction detected an aberrant fusion transcript, where the light chain (LC) constant domain sequence was fused to the 3' end of the HC transcript. Translation of this fusion transcript generated an extended peptide sequence at the HC C-terminus corresponding to the observed 11 kDa mass addition. Nanopore-based genome sequencing showed multiple copies of the plasmid had integrated in tandem with one copy missing the 5' end of the plasmid, deleting the LC variable domain. The fusion transcript was due to read-through of the HC terminator sequence into the adjacent partial LC gene and an unexpected splicing event between a cryptic splice-donor site at the 3' end of the HC and the splice acceptor site at the 5' end of the LC constant domain. Our study demonstrates that combining protein physicochemical characterization with genomic and transcriptomic analysis of the manufacturing cell line greatly improves the identification of sequence variants and understanding of the underlying molecular mechanisms.

Indexed as

Antibodies, MonoclonalImmunoglobulin GImmunoglobulin Heavy ChainsAnimalsCHO CellsChromatography, LiquidCricetulusHigh-Throughput Nucleotide SequencingMiceProtein DomainsTandem Mass SpectrometryAntibodies, MonoclonalImmunoglobulin GImmunoglobulin Heavy Chainsaberrant fusion proteinalternative splicingexpression vectorFc-extensionhigh throughput sequencingLC/MSmonoclonal antibodynanopore sequencingRT-PCRsequence variantsplice variants

Identifiers

PMID31570042
PMCPMC6816433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.